Role of Pancreatic Tumour-Derived Exosomes and Their Cargo in Pancreatic Cancer-Related Diabetes DOI Open Access

Helen Binang,

Chamini J. Perera, Minoti V. Apte

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(12), P. 10203 - 10203

Published: June 15, 2023

One of the most common and deadly types pancreatic cancer (PC) is ductal adenocarcinoma (PDAC), with patients succumbing to disease within one year diagnosis. Current detection strategies do not address asymptomatic PC; therefore, are diagnosed at an advanced stage when curative treatment often no longer possible. In order detect PC in earlier, risk factors that could serve as reliable markers need be examined. Diabetic mellitus (DM) a significant factor for this malignancy can both cause consequence PC. Typically, DM caused by known new-onset, pancreatogenic, pancreoprivic, or cancer-related diabetes (PCRD). Although PCRD quite distinct from type 2 (T2DM), there currently biomarkers differentiate T2DM. To identify such biomarkers, better understanding mechanisms mediating essential. end, has been growing research interest recent years elucidate role tumour-derived exosomes their cargo pathogenesis PCRD. Exosomes derived tumours recognized specificity because they reflect characteristics parent cells important intercellular communication. Their consists proteins, lipids, nucleic acids, which transferred alter behaviour recipient cells. This review provides concise overview current knowledge regarding discusses potential areas worthy further study.

Language: Английский

Epigenetic modifications: Key players in cancer heterogeneity and drug resistance DOI Creative Commons
Hana Q. Sadida,

Alanoud Abdulla,

Sara Al Marzooqi

et al.

Translational Oncology, Journal Year: 2023, Volume and Issue: 39, P. 101821 - 101821

Published: Nov. 4, 2023

Cancer heterogeneity and drug resistance remain pivotal obstacles in effective cancer treatment management. One major contributor to these challenges is epigenetic modifications - gene regulation that does not involve changes the DNA sequence itself but significantly impacts expression. As we elucidate phenomena, underscore role of regulating expression, contributing cellular diversity, driving adaptive can instigate therapeutic resistance. This review dissects essential methylation, histone modifications, chromatin remodeling illustrating their significant yet complex contributions biology. While offer potential avenues for intervention due reversible nature, interplay genetic cells presents unique must be addressed harness full potential. By critically analyzing current research landscape, identify knowledge gaps propose future directions, exploring therapies discussing translating concepts into treatments. comprehensive aims stimulate further aid developing innovative, patient-centered therapies. Understanding critical scientific advancement paves way towards improving patient outcomes fight against this formidable disease.

Language: Английский

Citations

52
Big data: Historic advances and emerging trends in biomedical research DOI Creative Commons

Conor J. Cremin,

Sabyasachi Dash, Xiaofeng Huang

et al.

Current Research in Biotechnology, Journal Year: 2022, Volume and Issue: 4, P. 138 - 151

Published: Jan. 1, 2022

Big data is transforming biomedical research by integrating massive amounts of from laboratory experiments, clinical investigations, healthcare records, and the internet things. Specifically, increasing rate at which information obtained omics technologies (genomics, epigenomics, transcriptomics, proteomics, metabolomics, pharmacogenomics) providing an opportunity for future advances in personalized medicine that are paving way to improved patient care. The recent profoundly contributing big biomedicine anticipated aid disease diagnosis care management. Herein, we critically review major computational techniques, algorithms, their outcomes have contributed generated various complex human diseases, such as cancer infectious diseases. Finally, discuss trends field directions must be considered advance influence on its translation industry.

Language: Английский

Citations

41
Unlocking the potential of non-coding RNAs in cancer research and therapy DOI Creative Commons
Kalyan Ram Uppaluri, Hima Jyothi Challa, Ashish Gaur

et al.

Translational Oncology, Journal Year: 2023, Volume and Issue: 35, P. 101730 - 101730

Published: July 3, 2023

Non-coding RNAs (ncRNAs) have emerged as key regulators of gene expression, with growing evidence implicating their involvement in cancer development and progression. The potential ncRNAs diagnostic prognostic biomarkers for is promising, emphasis on use liquid biopsy tissue-based diagnostics. In a nutshell, the review comprehensively summarizes diverse classes implicated cancer, including microRNAs, long non-coding RNAs, circular functions mechanisms action. Furthermore, we describe therapeutic applications ncRNAs, anti-miRNA oligonucleotides, siRNAs, other RNA-based therapeutics treatment. However, significant challenges remain developing effective ncRNA-based diagnostics therapeutics, lack specificity, limited understanding mechanisms, delivery challenges. This also covers current state-of-the-art RNA research technologies bioinformatic analysis tools. Lastly, outline future directions novel biomarkers, targets, modalities. summary, this provides comprehensive clinical applications, highlighting both opportunities rapidly evolving field.

Language: Английский

Citations

33
Non‐coding RNAs in cancer immunotherapy: Predictive biomarkers and targets DOI Creative Commons
Murad Alahdal, Eyad Elkord

Clinical and Translational Medicine, Journal Year: 2023, Volume and Issue: 13(9)

Published: Sept. 1, 2023

Abstract Background To date, standardising clinical predictive biomarkers for assessing the response to immunotherapy remains challenging due variations in personal genetic signatures, tumour microenvironment complexities and epigenetic onco‐mechanisms. Main body Early monitoring of key non‐coding RNA (ncRNA) may help predicting efficacy cancer come up with standard ncRNA biomarkers. For instance, reduced miR‐125b‐5p level plasma non‐small cell lung patients treated anti‐PD‐1 predicts a positive outcome. The miR‐153 colorectal chimeric antigen receptor T lymphocyte (CAR‐T) therapy indicate activation T‐cell killing activity. miR‐148a‐3p miR‐375 levels forecast favourable responses CAR‐T‐cell B‐cell acute lymphoblastic leukaemia. In GPC3 peptide vaccine, serum miR‐1228‐5p, miR‐193a‐5p miR‐375‐3p were reported as good improved overall survival. Therefore, there is critical need further studies elaborate on that have potential predict early immunotherapy. Conclusion This review summarises important different immunotherapeutic modalities, including monoclonal antibodies, small molecule inhibitors, vaccines CAR‐T cells. addition, concise discussion forthcoming perspectives provided, outlining technical approaches optimal utilisation immunomodulatory tools therapeutic targets.

Language: Английский

Citations

28
The potential role of circular RNAs -regulated PI3K signaling in non-small cell lung cancer: Molecular insights and clinical perspective DOI

Samaneh Kahkesh,

Seyedeh Mahdieh Khoshnazar,

Yasaman Gholinezhad

et al.

Pathology - Research and Practice, Journal Year: 2024, Volume and Issue: 257, P. 155316 - 155316

Published: April 16, 2024

Language: Английский

Citations

12
Nanomaterials‐Based Targeting of Long Non‐Coding RNAs in Cancer: A Cutting‐Edge Review of Current Trends DOI
Fatemeh Davodabadi, Bahareh Farasati Far, Saman Sargazi

et al.

ChemMedChem, Journal Year: 2024, Volume and Issue: 19(8)

Published: Jan. 24, 2024

This review article spotlights the burgeoning potential of using nanotherapeutic strategies to target long non-coding RNAs (lncRNAs) in cancer cells. updated discourse underlines prominent role lncRNAs instigating cancer, facilitating its progression, and metastasis, validating lncRNAs' for being effective diagnostic biomarkers therapeutic targets. The manuscript offers an in-depth examination different presently employed modulate lncRNA expression function purposes. Among these strategies, Antisense Oligonucleotides (ASOs), RNA interference (RNAi) technologies, innovative clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing tools garner noteworthy mention. A significant section is dedicated nanocarriers their crucial drug delivery. These nanocarriers' efficiency targeting varied types cancers elaborated upon, importance targeted therapy. culminates by reaffirming promising prospects enhance accuracy diagnosis improve treatment efficacy. Consequently, new paths are opened more research innovation employing approaches against Thus, this comprehensive serves as a valuable resource that underscores vital various nano-strategies them treatment. Future should also focus on unraveling complex regulatory networks involving identifying fundamental functional interactions refine cancer.

Language: Английский

Citations

11
Comprehensive insights and In silico analysis into the emerging role of LincRNAs in lung diseases pathogenesis; a step toward ncRNA precision DOI Creative Commons
Nadia Μ. Hamdy, Mohamed Bakr Zaki, Nourhan M. Abdelmaksoud

et al.

Functional & Integrative Genomics, Journal Year: 2025, Volume and Issue: 25(1)

Published: Feb. 6, 2025

Abstract Long non-coding RNAs (lncRNAs) have emerged as essential regulators of gene expression, significantly influencing various biological processes. Approximately half all lncRNAs are classified long intergenic (lincRNAs), which situated among coding genes. Recent studies documented the role lincRNAs in pathogenesis lung diseases, including cancer, pulmonary fibrosis, and arterial hypertension. These can modulate expression through mechanisms, epigenetic modifications, transcriptional regulation, post-transcriptional regulation. By functioning competing endogenous (ceRNAs), affect activity microRNAs (miRNAs) their corresponding target This review delves into intricate mechanisms by contribute to development progression diseases. Furthermore, it discusses potential therapeutic targets.

Language: Английский

Citations

1
LINC00894, YEATS2-AS1, and SUGP2 genes as novel biomarkers for N0 status of lung adenocarcinoma DOI Creative Commons
Marzyeh Alipour, Mehdi Moghanibashi, Sirous Naeimi

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: March 27, 2025

Research on genes affecting tumors without lymph node metastasis is limited, hence this study employed both bioinformatic and experimental approaches to identify specific associated with lung cancer adenocarcinoma (LUAD) before occurs. Expression profiles of mRNAs lncRNAs LUAD clinical data were downloaded from the Cancer Genome Atlas (TCGA) using R software differentially expressed (DEGs) N0 N + status. TargetScan, miRTarBase, miRDB databases used interactions between miRNAs mRNAs. The DIANA database lncBase tool find association lncRNA miRNA. After selecting some genes, expression candidate was confirmed by real-time RT-PCR technique. Following knockdown LINC00894 gene shRNA technique, its effect invasion, migration, apoptosis in calu-3 cell line investigated. In total, we found 321 DEGs not only vs. normal but also Vs. LUAD, most which identified a ceRNA network containing nine highest degree connectivity. Among them, addition analyses, YEATS2-AS1 significantly increased tumor tissues compared (P = 0.0001). also, SUGP2 that shared lncRNA-related subnetworks upregulated Additionally, following Calu-3 line, significant decrease migration invasion observed, early shLINC00894(48 h) group 0.007). findings present show play an important role status LUAD. Moreover, LINC00894, YEATS2-AS1, can act as biomarkers patients

Language: Английский

Citations

1
Advances in the Molecular Landscape of Lung Cancer Brain Metastasis DOI Open Access
Vanessa G. P. Souza, Rachel Paes de Araújo, Mariana R. Santesso

et al.

Cancers, Journal Year: 2023, Volume and Issue: 15(3), P. 722 - 722

Published: Jan. 24, 2023

Lung cancer is one of the most frequent tumors that metastasize to brain. Brain metastasis (BM) common in advanced cases, being major cause patient morbidity and mortality. BMs are thought arise via seeding circulating tumor cells into brain microvasculature. In tissue, interaction with immune promotes a microenvironment favorable growth cells. Despite multimodal treatments advances systemic therapies, lung patients still have poor prognoses. Therefore, there an urgent need identify molecular drivers BM clinically applicable biomarkers order improve disease outcomes survival. The goal this review summarize current state knowledge on mechanisms metastatic spread how influenced by microenvironment, elucidate determinants regarding role genomic transcriptomic changes, including coding non-coding RNAs. We also present overview therapeutics novel treatment strategies for diagnosed from NSCLC.

Language: Английский

Citations

20
Engineered smart materials for RNA based molecular therapy to treat Glioblastoma DOI Creative Commons

Ravi Raj Singh,

Indranil Mondal, Taskeen Iqbal Janjua

et al.

Bioactive Materials, Journal Year: 2023, Volume and Issue: 33, P. 396 - 423

Published: Nov. 27, 2023

Glioblastoma (GBM) is an aggressive malignancy of the central nervous system (CNS) that remains incurable despite multitude improvements in cancer therapeutics. The conventional chemo and radiotherapy post-surgery have only been able to improve prognosis slightly; however, development resistance and/or tumor recurrence almost inevitable. There a pressing need for adjuvant molecular therapies can successfully efficiently block progression. During last few decades, non-coding RNAs (ncRNAs) emerged as key players regulating various hallmarks including GBM. levels many ncRNAs are dysregulated cancer, ectopic modulation their by delivering antagonists or overexpression constructs could serve attractive option therapy. therapeutic potential several types ncRNAs, miRNAs, lncRNAs, circRNAs, has validated both vitro vivo models However, delivery these RNA-based therapeutics highly challenging, especially tumors brain blood-brain barrier (BBB) poses major obstacle, among others. Also, since RNA extremely fragile nature, careful considerations must be met while designing agent. In this review we shed light on how ncRNA therapy overcome limitations its predecessor with emphasis smart nanomaterials aide safe targeted nucleic acids treat Additionally, critical gaps currently exist successful transition from viral non-viral vector systems identified. Finally, provided perspective future directions, pathways, target areas achieving rapid clinical translation of, macromolecular advance effective treatment GBM other related diseases.

Language: Английский

Citations

17